Doximity Ask

What is Doximity Ask and who sells it?

The product is called Doximity Ask and is used behind a login at doximity.com/ask (tooldirectory.ai). Vendor and press coverage describe it as free and HIPAA-compliant for verified US clinicians. The HIPAA statement is the vendor's claim. BAA terms and SOC 2 status are not published.

Doximity, Inc. was founded in 2010 and is a public company (NYSE: DOCS). It acquired Pathway Medical for $26 million in cash plus up to $37 million in equity, about $63 million in total, and the deal closed on 29 July 2025 (Fierce Healthcare).

What does it do?

A third-party directory, Doxiverse, lists more than 3,200 drug monographs and the drafting and faxing of prior-auth and appeal letters. A feature called PeerCheck has physicians review AI output. Doximity's own report states that the tool gives full PDF access to more than 2,000 journals. Vera Health, a competitor, writes that Ask has no EHR integration.

What does it cost?

Nothing for verified US clinicians. Third-party write-ups say it is paid for by pharmaceutical and health-system advertising, and that it is also part of enterprise contracts with more than 150 health systems.

What does the evidence say?

Two sets of numbers exist. The first is a July 2026 benchmark called NOHARM, run by researchers described in the press as Stanford, Harvard and ARISE. Doximity Ask scored top, and OpenEvidence disputed the result and said the study was not peer-reviewed (Fortune, 29 July 2026). The same study found that 76.6% of harmful errors across all tools were omissions, a finding that applies to the whole category.

The second is Doximity's Q4 2025 physician survey, in which 61% preferred Ask against 26% for the alternative (Doximity press report). The company ran that survey itself. No independent accuracy study of Ask is published.

How does it compare?

UpToDate Expert AI answers only from UpToDate's library and costs $699 a year in the Pro Plus tier (Wolters Kluwer, July 2026), while Ask costs nothing. OpenEvidence is the rival that contested the NOHARM result.

Who is it for?

An outpatient physician or resident who wants a free second reference for drug questions and letter drafting gets the most out of it. A hospital looking for a tool with independent validation behind it has no such study to cite yet.

The verdict

For letters and drug lookups the price makes Ask an easy addition to a clinician's tools. For decisions that carry risk, the accuracy evidence is a vendor survey and a contested benchmark, so Ask belongs next to a second source.